Cutaneous

89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial No disease recurrence among the…

Allogeneic hematopoietic stem cell transplantation (HSCT) was associated with…

At the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting last month, Elizabeth…

ZUG, Switzerland and BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for…

WATERTOWN, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver…

PARIS -- Neoadjuvant therapy with cemiplimab (Libtayo) achieved deep pathologic responses in patients with resectable cutaneous…

Physician’s Briefing Staff MONDAY, Sept. 12, 2022 (HealthDay News) -- Fifty-one percent of patients receiving neoadjuvant therapy with cemiplimab for…

Treatment with an investigational drug targeting the blood dendritic cell antigen 2 (BDCA2)…

The Indiana Center for Regenerative Medicine and Engineering (ICRME) at Indiana University School of Medicine is home to tissue nanotransfection (TNT) regenerative medicine technology that…

New York, July 15, 2022 (GLOBE NEWSWIRE) -- The different types of cancer that arise in the immune cells, also known as lymphocytes, are commonly termed as lymphoma. It is estimated that…